Clinical biochemistry · 2025
The diagnostic value of citrullinated antigens with multiple citrulline similar motif in patients with rheumatoid arthritis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Guihua, Cai Long, Liu Libin, Liu Yongxia, Zhang Li, Li Zhihui
Аннотация
BACKGROUND AND AIMS: Anti-cyclic citrulline peptide (anti-CCP) antibodies are among the most critical biomarkers for the diagnosis of rheumatoid arthritis (RA), with citrullinated antigens being pivotal in triggering their production. This study aimed to explore the potential diagnostic value of multiple citrulline similar-motif antigen (MCSM) in RA.
MATERIAL AND METHODS: A retrospective study was conducted on 135 patients with RA, 112 patients with other joint diseases (non-RA group), and 67 healthy controls from the Hangzhou Red Cross Hospital. The levels of MCSM in the peripheral blood were measured. The diagnostic value of MCSM in RA patients was assessed by receiver operating characteristic (ROC) curve analysis.
RESULTS: MCSM in serum were significantly higher in RA patients than in non-RA patients (Signal-to-Cutoff ratio (S/CO): 3.2 vs 0.5, P < 0.0001) and healthy controls (S/CO: 3.2 vs 0.4, P < 0.0001). ROC analysis showed an area under the curve (AUC) of 0.932 for MCSM. Individually, MCSM outperformed anti-CCP and rheumatoid factor (RF), achieving sensitivity of 91.1 % and specificity of 95.5 %. Notably, MCSM detection rates were significantly higher in RA patients with pain duration under one year compared to anti-CCP (89.47 % vs. 52.65 %, P < 0.05).
CONCLUSION: MCSM demonstrate high sensitivity and specificity in diagnosing RA, with significant complementary value to anti-CCP and RF, and can increase the detection rate among RA patients with a disease duration of less than one year.
MATERIAL AND METHODS: A retrospective study was conducted on 135 patients with RA, 112 patients with other joint diseases (non-RA group), and 67 healthy controls from the Hangzhou Red Cross Hospital. The levels of MCSM in the peripheral blood were measured. The diagnostic value of MCSM in RA patients was assessed by receiver operating characteristic (ROC) curve analysis.
RESULTS: MCSM in serum were significantly higher in RA patients than in non-RA patients (Signal-to-Cutoff ratio (S/CO): 3.2 vs 0.5, P < 0.0001) and healthy controls (S/CO: 3.2 vs 0.4, P < 0.0001). ROC analysis showed an area under the curve (AUC) of 0.932 for MCSM. Individually, MCSM outperformed anti-CCP and rheumatoid factor (RF), achieving sensitivity of 91.1 % and specificity of 95.5 %. Notably, MCSM detection rates were significantly higher in RA patients with pain duration under one year compared to anti-CCP (89.47 % vs. 52.65 %, P < 0.05).
CONCLUSION: MCSM demonstrate high sensitivity and specificity in diagnosing RA, with significant complementary value to anti-CCP and RF, and can increase the detection rate among RA patients with a disease duration of less than one year.